TABLE 4.

Adverse events by treatment assignment

Event	Placebo	Metformin	Troglitazone	ILS
n	582	587	585	589
CHF	0 (0.0)	1 (0.2)	0 (0.0)	1 (0.2)
MI	2 (0.3)	0 (0.0)	0 (0.0)	2 (0.3)
Anemia	7 (1.2)	5 (0.9)	7 (1.2)	4 (0.7)
Edema	31 (5.3)	8 (1.4)	27 (4.6)	26 (4.4)
LFT ≥3	21 (3.6)	18 (3.1)	25 (4.3)	NA
LFT ≥10	1 (0.2)	0 (0.0)	7 (1.2)	NA

Data are n (%) of individuals in each randomization group experiencing at least one adverse event of the type specified. Liver function tests were not measured on the same schedule in the ILS group. CHF, congestive heart failure; MI, myocardial infarction; LFT ≥3, liver function test (either alanine aminotransferase or aspartate aminotransferase) ≥3 times the upper limit of normal; LFT ≥10, liver function test (either alanine aminotransferase or aspartate aminotransferase) ≥10 times the upper limit of normal; NA, not applicable.